



June 15, 2020

Re: Peroxigard™ efficacy against Rabbit Hemorrhagic Disease Virus 2 (RHDv2)

Dear Sir or Madam,

In cases of emerging viral pathogens such as Rabbit Hemorrhagic Disease Virus 2 (RHDv2), when there is no test that can be conducted to validate the efficacy of a disinfectant, the EPA utilizes Emerging Viral Pathogen Guidance to determine the expected efficacy of a disinfectant against an emerging virus. In the case of a small non-enveloped virus such as RHDv2, the following criteria are used to determine efficacy of a disinfectant upon activation of the Emerging Pathogen Rule:

1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. The product must have acceptable efficacy data previously submitted to and reviewed by the Agency against two small non-enveloped viruses, each from a different family.

The Peroxigard™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) fulfill these criteria and therefore can be used against RHDv2 as part of a facility's infection prevention and control plan on hard, non-porous surfaces. Peroxigard™ concentrate (EPA# 74559-4) should be applied at a 1:16 dilution for a contact time of five minutes. Peroxigard™ ready-to-use liquid (EPA# 74559-9) and wipes (EPA# 74559-10) should be applied with a one-minute contact time. Refer to the Animal and Plant Health Inspection Service website for more information (<https://www.aphis.usda.gov/aphis/home/>).

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at nkenny@virox.com.

Best Regards,

Nicole Kenny, HBS_c., Assoc Chem
Vice President, Professional and Technical Services
Virox Technologies Inc.